A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Degarelix (Primary) ; Letrozole; Triptorelin
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms TREND
- 12 Dec 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Mar 2018.
- 09 Dec 2017 Results of preliminary analysis (n=45) presented at the 40th Annual San Antonio Breast Cancer Symposium.
- 10 Jun 2017 Biomarkers information updated